Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.52, p.430-434, 2005 |
||
Title: The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia | ||
Author: J.M., HORACEK ; R., PUDIL ; M., TICHY ; L., JEBAVY ; A., STRASOVA ; R., PRAUS ; P., ZAK ; J., MALY ; | ||
Abstract: Cardiotoxicity is a serious and relatively frequent complication of antitumorous treatment. Anthracyclines represent the
greatest risk. Biochemical markers of structural and functional myocardial damage have been gaining ground in
cardiotoxicity monitoring. The aim of the study was to monitor cardiotoxicity of induction chemotherapy in acute myeloid
leukemia (AML) patients and to assess the potential for use of biochemical markers in early diagnostics of cardiotoxicity.
Fifteen consecutive adult patients with a newly diagnosed AMLwere studied. All patients received induction chemotherapy
containing Idarubicin (IDA) 3x12 mg/m2 and intermediate doses of Cytarabine (8x1.5 g/m2). Serial measurements of plasma
N-terminal pro brain natriuretic peptide (NT-proBNP) values were performed at the baseline, the day following each IDA
infusion, after 14 days and after circa 1 month, i.e. before the next chemotherapy. Cardiospecific markers (cTnT, CK-MB
mass) were measured at the baseline and after the last IDA infusion. The mean baseline value of NT-proBNP in newly diagnosed
AML patients was 129.7±59.6 pg/ml. The mean NT-proBNP value increased after the first IDA infusion to
307.3±171.4 pg/ml (p=0.02). In most of the patients, the second and the third IDA infusions were not associated with a further
increase in the NT-proBNP value and levels after 2 and 4 weeks were not significantly different from the baseline. However,
in one of the patients the NT-proBNP values were increasing after each IDA infusion (after the last one 786.2 pg/ml)
and within 14 days he developed congestive heart failure due to left ventricular diastolic dysfunction as assessed by
echocardiography. At that time, the NT-proBNP value was 1184.0 pg/ml; after diuretics it decreased significantly. In all patients,
plasma cTnT and CK-MB mass concentrations were within the reference interval at the baseline and after the induction
chemotherapy. Our results suggest that induction chemotherapy in AML (IDA 36 mg/m2 and intermediate doses of
Cytarabine): 1. does not cause detectable damage of the myocyte structure, 2. is in all patients associated with acute
neurohumoral activation (transient elevation of NT-proBNP) indicating acute subclinical cardiotoxicity, 3. may lead to congestive
heart failure and NT-proBNP seems to be a promising early marker and predictor of this complication.
|
||
Keywords: NT-proBNP, cardiospecific markers, cardiotoxicity, Idarubicin, acute leukemia | ||
Year: 2005, Volume: 52, Issue: | Page From: 430, Page To: 434 | |
|
download file |
|